Year: 2019
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Reports that sodium glucose cotransporter 2 inhibitors decrease cardiovascular death and events in patients with diabetes have attracted attention in the cardiology field. We conducted a study of canagliflozin in patients with chronic heart failure and type II diabetes. METHODS: Thirty-five Japanese patients with chronic heart failure and type II diabetes were treated with canagliflozin for 12 months. The primary endpoints were the changes of subcutaneous, visceral, and total fat areas at 12 months determined by computed tomography. Secondary endpoints included markers of glycemic control, renal function, and oxidative stress, as well as lipid parameters, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), flow-mediated dilation (FMD), and echocardiographic left ventricular function. RESULTS: All fat areas (subcutaneous, visceral, and total) showed a significant decrease at 12 months. ANP and BNP also decreased significantly, along with improvement of renal function, oxidized LDL, and E/e', FMD increased significantly after canagliflozin treatment. CONCLUSION: Canagliflozin demonstrated cardiac and renal protective effects as well as improving oxidative stress, diastolic function, and endothelial function. This drug was effective in patients who had heart failure with preserved ejection fraction and could become first-line therapy for such patients with diabetes. Trial registration UMIN ( http://www.umin.ac.jp/ ), Study ID: UMIN000021239.
Source: Cardiovascular Diabetology
Institution: Nihon University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: canagliflozin, SGLT2 inhibitors, chronic heart failure, type 2 diabetes, heart failure with preserved ejection fraction, visceral fat, subcutaneous adipose tissue, renal function, oxidative stress, oxidized LDL, endothelial function, flow-mediated dilation, natriuretic peptides, left ventricular diastolic function, Japanese patients
Open Access status: gold
Estimated APC paid: $3,060
OpenAlex ID: W2948029031
